Filing Flows › Chemed (CHE) › Q2 2026 › vs Q2 2025
Chemed (CHE) Q2 2026 vs Q2 2025 (year over year)
Chemed's revenue rose $54.5M (+9%) from $619M in Q2 2025 to $673M in Q2 2026. The biggest changes: VITAS +$47.1M (+12%); Roto-Rooter +$7.3M (+3%). Operating margin 13.2% against 11.0% (+2.2 pts).
Chemed, Q2 2026: revenue $673M (+9% year over year), operating margin 13.2%, net earnings $67.7M, operating cash flow $84.8M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 13.2% | 11.0% | +2.2 pts |
| Net margin | 10.1% | 8.5% | +1.6 pts |
| Free cash flow margin | 10.3% | 19.8% | -9.6 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| VITAS | $443M | $396M | $47.1M | +12% |
| Roto-Rooter | $230M | $223M | $7.3M | +3% |
| Revenue | $673M | $619M | $54.5M | +9% |
| Other income, net | $2.1M | $3.0M | −$906K | -30% |
| Operating profit | $89.2M | $68.1M | $21.1M | +31% |
| Costs & expenses | $584M | $551M | $33.3M | +6% |
| Pre-tax earnings | $91.3M | $71.1M | $20.2M | +28% |
| Cost of revenue | $452M | $434M | $17.7M | +4% |
| SG&A | $115M | $100M | $14.9M | +15% |
| Other operating costs | $17.1M | $16.3M | $778K | +5% |
| Net earnings | $67.7M | $52.5M | $15.2M | +29% |
| Income tax | $23.6M | $18.6M | $5.0M | +27% |
| Depreciation & amortization | $17.0M | $16.3M | $726K | +4% |
| Working capital & other | $124K | $69.9M | −$69.7M | -100% |
| Operating cash flow | $84.8M | $139M | −$53.8M | -39% |
| Free cash flow (OCF − capex) | $69.3M | $123M | −$53.5M | -44% |
| Capital expenditures | $15.5M | $15.8M | −$287K | -2% |
Questions
How much did Chemed's revenue grow year over year in Q2 2026?
Chemed's revenue rose $54.5M (+9%) from $619M in Q2 2025 to $673M in Q2 2026.
What drove Chemed's revenue change in Q2 2026?
VITAS +$47.1M (+12%); Roto-Rooter +$7.3M (+3%).